<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02964936</url>
  </required_header>
  <id_info>
    <org_study_id>1517-CL-0314</org_study_id>
    <nct_id>NCT02964936</nct_id>
  </id_info>
  <brief_title>A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, 2-Arm, Open-label Study of Intermittent Oral Dosing of ASP1517 for the Treatment of Anemia in Erythropoiesis Stimulating Agent-untreated Chronic Kidney Disease Patients Not on Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FibroGen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy and the safety when ASP1517 is
      intermittently administered in Erythropoiesis Stimulating Agent (ESA)-untreated non-dialysis
      chronic kidney disease patients with anemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 11, 2017</start_date>
  <completion_date type="Actual">August 15, 2018</completion_date>
  <primary_completion_date type="Actual">August 15, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in hemoglobin (Hb) response rate</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>Hb response is defined as reaching target values for Hb.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the average Hb from Week 18 to Week 24</measure>
    <time_frame>Baseline and Weeks 18 to 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who achieve the target Hb level at the average of Week 18 to 24</measure>
    <time_frame>Weeks 18 to 24</time_frame>
    <description>Hb response defined as average Hb within the target range in this outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of rise in Hb levels (g/dL/week) from week 0 at the earliest date of week 4, time to discontinuation, or time of dose adjustment</measure>
    <time_frame>Up to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of measurement points with the target Hb level</measure>
    <time_frame>Weeks 18 to 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who achieves the target Hb level at each week</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who achieves the lower limit of the target Hb level</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve the lower limit of the target Hb level</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Hb level to each week</measure>
    <time_frame>Baseline and Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by EQ-5D-5L</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>EQ-5D: EuroQol 5 Dimension 5 Levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by FACT-An</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>FACT-An: Functional Assessment of Cancer Therapy-Anemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal Vital signs and/or adverse events related to treatment</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by body weight</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by incidence of adverse events</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by standard 12-lead electrocardiogram</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal Laboratory values and/or adverse events related to treatment</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of unchanged ASP1517</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average hematocrit level</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average reticulocyte level</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average iron (Fe) level</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average ferritin level</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average transferrin level</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average total iron binding capacity level</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average soluble transferrin receptor level</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average transferrin saturation level</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average reticulocyte hemoglobin content level</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalizations</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalizations</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>ASP1517 Low dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study drug will be dosed three times weekly for 24 weeks and dose adjustments will be made during the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP1517 High dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study drug will be dosed three times weekly for 24 weeks and dose adjustments will be made during the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>roxadustat</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>ASP1517 High dose group</arm_group_label>
    <arm_group_label>ASP1517 Low dose group</arm_group_label>
    <other_name>ASP1517</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who were diagnosed with non-dialysis chronic kidney disease (CKD) and who are
             considered not to require renal replacement therapy during the study period

          -  Mean of the subject's two most recent Hb values before randomization during the
             Screening Period must be &lt;10.5 g/dL with an absolute difference ≤1.3 g/dL between the
             two values

          -  Either transferrin saturation ≥ 5% or serum ferritin ≥ 30 ng/mL

          -  Female subject must either:

        Be of non-childbearing potential:

          -  post-menopausal prior to pre-screening, or

          -  documented surgically sterile Or, if of childbearing potential,

          -  Agree not to try to become pregnant during the study after informed consent
             acquisition and for 28 days after the final study drug administration

          -  And have a negative urine pregnancy test at pre-screening

          -  And, if heterosexually active, agree to consistently use two forms of highly effective
             birth control (at least one of which must be a barrier method) starting at
             pre-screening and throughout the study period and for 28 days after the final study
             drug administration.

          -  Female subject must agree not to breastfeed starting at pre-screening and throughout
             the study period, and for 28 days after the final study drug administration.

          -  Female subject must not donate ova starting at pre-screening and throughout the study
             period, and for 28 days after the final study drug administration.

          -  Male subject and their female spouse/partners who are of childbearing potential must
             be using two forms of highly effective birth control (at least one of which must be a
             barrier method) starting at pre-screening and continue throughout the study period,
             and for 12 weeks after the final study drug administration

          -  Male subject must not donate sperm starting at pre-screening and throughout the study
             period, and for 12 weeks after the final study drug administration

        Exclusion Criteria:

          -  Concurrent retinal neovascular lesion requiring treatment and macular edema requiring
             treatment

          -  Concurrent autoimmune disease with inflammation that could impact erythropoiesis

          -  History of gastric/intestinal resection considered influential on the absorption of
             drugs in the gastrointestinal tract (excluding resection of gastric or colon polyps)
             or concurrent gastroparesis

          -  Uncontrolled hypertension

          -  Concurrent congestive heart failure (NYHA Class III or higher)

          -  History of hospitalization for treatment of stroke, myocardial infarction, or
             pulmonary embolism within 12 weeks before the pre-screening assessment

          -  Positive for hepatitis B surface antigen (HBsAg) or anti-hepatitis C virus (HCV)
             antibody at the pre-screening assessment, or positive for human immunodeficiency virus
             (HIV) in a past test

          -  Concurrent other form of anemia than renal anemia

          -  Having received treatment with ESA, protein anabolic hormone, testosterone enanthate,
             or mepitiostane within 6 weeks before the pre-screening assessment

          -  Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) or total bilirubin
             that is greater than the criteria, or previous or concurrent another serious liver
             disease at pre-screening assessment

          -  Previous or current malignant tumor (no recurrence for at least 5 years is eligible.)

          -  Having undergone red blood transfusion and/or a surgical procedure considered to
             promote anemia within 4 weeks before the pre-screening assessment

          -  Having undergone a kidney transplantation

          -  History of serious drug allergy including anaphylactic shock

          -  Having a previous history of treatment with ASP1517

          -  Participation in another clinical study or post-marketing clinical study (including
             that of a medical device) within 12 weeks before informed consent acquisition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site JP00007</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00018</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00028</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00001</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00035</name>
      <address>
        <city>Ehime</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00012</name>
      <address>
        <city>Fukui</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00011</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00031</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00030</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00034</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00036</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00005</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00020</name>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00015</name>
      <address>
        <city>Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00017</name>
      <address>
        <city>Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00021</name>
      <address>
        <city>Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00025</name>
      <address>
        <city>Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00037</name>
      <address>
        <city>Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00033</name>
      <address>
        <city>Ishikawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00029</name>
      <address>
        <city>Iwate</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00006</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00014</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00038</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00010</name>
      <address>
        <city>Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00016</name>
      <address>
        <city>Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00024</name>
      <address>
        <city>Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00032</name>
      <address>
        <city>Oita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00003</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00009</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00026</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00002</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00019</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00027</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00004</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00013</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00022</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00023</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00008</name>
      <address>
        <city>Toyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>November 13, 2016</study_first_submitted>
  <study_first_submitted_qc>November 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2016</study_first_posted>
  <last_update_submitted>August 13, 2019</last_update_submitted>
  <last_update_submitted_qc>August 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anemia</keyword>
  <keyword>Non-dialysis chronic kidney disease</keyword>
  <keyword>Roxadustat</keyword>
  <keyword>ASP1517</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.</ipd_time_frame>
    <ipd_access_criteria>Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.</ipd_access_criteria>
    <ipd_url>https://www.clinicalstudydatarequest.com/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

